

MAR 1 7 2004

SUMMARY OF SAFETY AND EFFECTIVENESS DATA RELATING TO SUBSTANTIAL EQUIVALENCE

Proprietary Name: Fabius GS Anesthesia System

Classification Name: Gas Machine, Anesthesia – 73 BSZ

Device Class II

Initial Distributor: Draeger Medical, Inc.

3135 Quarry Road

Telford, Pennsylvania 18969 USA

Establishment Registration No.: 2517967

Devices to which substantial

equivalence is claimed: Fabius GS Anesthesia System - K011404

Evita 4 Continuous Ventilator - K961687

Device Description:

The modified Fabius GS is a continuous flow gas anesthesia system.

Intended Use:

The modified Fabius GS may be used for spontaneous, manually assisted, automatic, or pressure support ventilation of patients during anesthesia, and delivery of gases and anesthetic vapor. The modified Fabius GS can monitor inspired oxygen concentration, breathing pressure, and respiratory volume.

Substantial Equivalence:

The current Fabius GS Anesthesia System (K011404) is being modified to include Pressure Support Ventilation as an optional ventilation mode. The addition of Pressure Support Ventilation is essentially a software change. The only hardware change was the addition of the Pressure Support hard key on the operator control panel. With the exception of minor incremental changes that did not require a 510(k) notification, the basic infrastructure, operating principle, alarm strategies, fault detection circuitry, and mechanical/pneumatic subassemblies within the Fabius GS remain unchanged from the initially released Fabius GS. Adjustable ventilation settings available in Pressure Support mode are Support Pressure Level, Trigger Level (sensitivity level at which a breath is detected), Maximum Inspiratory Flow, and Positive End Expiratory Pressure. Support Pressure Level and Trigger Level are new settings. Maximum Inspiratory Flow and Positive End Expiratory Pressure are ventilation settings already available to the user in the current automatic ventilation modes.

Like the Evita 4 Continuous Ventilator (K961687), Pressure Support Ventilation (PSV) in the Fabius GS is flow triggered and flow cycled.

Qualification of the modified Fabius GS included hazard analysis, system level qualification, and verification/validation tests.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAR 1 7 2004

Mr. Michael A. Kelhart Regulatory Affairs Project Manager Draeger Medical Incorporated 3135 Quarry Road Telford, PA 18969

Re: K030624

Trade/Device Name: Fabius GS Anesthesia System

Regulation Number: 868.5160

Regulation Name: Gas Machine, Anesthesia

Regulatory Class: II Product Code: BSZ Dated: February 18, 2004 Received: February 19, 2004

Dear Mr. Kelhart:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

Page 2 - Mr. Michael Kelhart

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

It Welochers

Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

			Page	1	of _	1
510(k) Number (if k	known):	K030624		<u> </u>		
Device Name:	Fabius GS	Anesthesia System				
Indications for Use	:					
be used for spontane	ous, manuall d anesthetic v tory volume	continuous flow anesth ly assisted, automatic ovapor, and monitoring of patients during anestof a physician.	or pressure s oxygen cond	upport v centratio	ventilai on, brea	non, athing
	,	O.D.	Over T	Cho Cou	ntar II	s a
Prescription Use (Per 21 CFR 801.10)9)	OR	Over-1	The-Cou	nter-O	se
	T WRITE B	ELOW THIS LINE	– CONTIN	UE ON	ANOT	THER
Con	currence of C	CDRH, Office of Devi	ce Evaluation	n (ODE))	
		(Division Sign-Off Division of Anestl Infection Control, 510(k) Number:	1esiology. Gei	es ,	spital,	